Thalassemia

Thalassemia is an inherited blood disorder that affects hemoglobin production. It ranges from mild carrier states to severe forms that require transfusion.

Thalassemia is a group of inherited disorders that disrupt the production of hemoglobin, the oxygen-carrying molecule in red blood cells. Because alpha or beta globin chain production is impaired, red blood cells can become smaller, more fragile, and less effective. In some people this causes only mild anemia, while in others the disease is severe enough to require regular blood transfusions, iron-overload monitoring, and specialist follow-up. Severity depends on the number of affected genes and the specific variant involved. ^[1][2]

Symptoms vary according to the form of the disease. Mild cases may cause no clear complaints and may be discovered incidentally because of a low MCV. More severe forms can lead to pallor, fatigue, shortness of breath, growth delay, jaundice, abdominal distension, and splenomegaly. In patients who need regular transfusions, iron accumulation over time can damage the heart, liver, and endocrine organs. ^[1][3]

Thalassemia is not contagious; it results from genetic changes inherited from the parents. In carrier couples, the risk of disease or carrier status in children depends on the inheritance pattern. For that reason, premarital or preconception screening and genetic counseling are important from a public-health perspective. The condition is more common in people of Mediterranean, Middle Eastern, South Asian, and African ancestry. ^[1][2]

Diagnosis relies on a complete blood count, peripheral smear, and distinction from iron deficiency. Hemoglobin electrophoresis or similar tests are commonly used to identify beta thalassemia. In alpha thalassemia, genetic testing may sometimes be required. Newborn screening, evaluation of those with a family history, and pre-pregnancy screening programs are valuable for early detection. ^[1][4]

Treatment is planned according to disease severity. In mild carrier states, no specific treatment is usually needed, but it is important to avoid inappropriate long-term iron therapy by making the correct differential diagnosis. In severe forms, regular transfusion, iron chelation, folate support, splenic assessment, and infection prevention become central. In selected patients, stem cell transplantation may offer a curative option. ^[1][2]

Monitoring iron overload is critically important. Although transfusions are life-saving, they can gradually lead to iron accumulation in the body. Ferritin monitoring, liver and cardiac MRI assessment, and appropriate chelation therapy aim to reduce long-term organ injury. If this surveillance is interrupted, serious complications may be recognized late. ^[1][3]

In carrier couples planning pregnancy, prenatal diagnosis and genetic counseling may be discussed. In children, growth, puberty, bone health, and school life should be monitored regularly. Fatigue, exercise tolerance, and psychosocial burden are also part of the treatment plan; focusing only on hemoglobin values is not enough. ^[1][4]

Situations that may require urgent care include marked pallor, shortness of breath, signs of infection, chest pain, a noticeable increase in jaundice, or symptoms suggesting a transfusion reaction. Management of severe thalassemia should always be coordinated with a hematology team. ^[1][2]

In summary, thalassemia is an inherited blood disorder that requires lifelong follow-up. Proper classification, an appropriate transfusion strategy, control of iron overload, and genetic counseling can reduce complications. Hematology assessment is essential for an individualized treatment plan. ^[1][3]

Prompt evaluation is a safer approach, especially when alarm symptoms are present.